Protagenic Therapeutics Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	5.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Protagenic Therapeutics non ha un CEO, o non abbiamo dati su di loro.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Garo Armen	Co-Founder & Executive Chairman of the Board	no data	Nessun dato	16.53% $ 449.0k
Robert Stein	Chief Medical Officer & Director	8.8yrs	Nessun dato	Nessun dato
Timothy Wright	Independent Director	2yrs	Nessun dato	Nessun dato
Brian Corvese	Independent Director	7.3yrs	US$118.75k	Nessun dato
Khalil Barrage	Independent Director	no data	US$243.75k	3.38% $ 91.7k
Jennifer Buell	Independent Director	4.3yrs	Nessun dato	Nessun dato

5.8yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PTIX sono considerati esperti (durata media dell'incarico 5.8 anni).

Protagenic Therapeutics Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Protagenic Therapeutics, Inc., Annual General Meeting, Dec 13, 2023

Protagenic Therapeutics, Inc. Appoints Timothy R. Wright as a Class I Director

Protagenic Therapeutics, Inc., Annual General Meeting, Nov 23, 2022

Recent updates

New major risk - Financial position

Protagenic Therapeutics, Inc. announced that it expects to receive $1.275 million in funding

Protagenic Therapeutics, Inc. Receives A Deficiency Letter from the Nasdaq Listing Qualifications Regarding Minimum Bid Price Requirement

New minor risk - Shareholder dilution

Protagenic Therapeutics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Set Forth in Nasdaq Listing Rule 5550(b)(1)

Protagenic Therapeutics, Inc. Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial

New major risk - Share price stability

New major risk - Financial position

Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders

Protagenic Therapeutics, Inc. to Report Q4, 2023 Results on Apr 01, 2024

New major risk - Share price stability

Protagonist Therapeutics, Inc. Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals

Protagenic Therapeutics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirements Set in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on The Nasdaq Capital Market

New minor risk - Shareholder dilution

Protagenic Therapeutics, Inc., Annual General Meeting, Dec 13, 2023

New minor risk - Share price stability

Protagenic Therapeutics, Inc. Appoints Timothy R. Wright as a Class I Director

Protagenic Therapeutics, Inc., Annual General Meeting, Nov 23, 2022

Protagenic Therapeutics, Inc. announced delayed annual 10-K filing

Protagenic Therapeutics, Inc's Common Stock Deleted from Other OTC

Protagenic Therapeutics, Inc. has completed a Composite Units Offering in the amount of $13.197 million.

Protagenic Therapeutics, Inc. Announces Dr. Maurizio Fava of Massachusetts General Hospital to Serve as Principal Investigator for PT00114 Clinical Trial

Protagenic Therapeutics, Inc. announced that it has received $2 million in funding

Protagenic Therapeutics, Inc. announced that it has received $0.4275 million in funding

Protagenic Therapeutics, Inc. announced that it expects to receive $0.475 million in funding

AMMINISTRATORE DELEGATO

Membri del Consiglio di amministrazione

Durata media

Età media